Cannabidivarin (CBDV)
OTHER NAME(S): 2-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-5-propylbenzene-1,3-diol, Cannabidiverol, CBD-V, CBDV, GWP42006, Cannabidivarin, Cannabidivarin, Cannabidivarina (CBDV), Cannabidivarine (CBDV)
Overview
Cannabidivarin (CBDV) is a chemical in the Cannabis sativa plant. It is similar to cannabidiol (CBD). Like CBD, cannabidivarin does not affect thinking.
Early research suggests that cannabidivarin might make certain nerve cells less active. These nerve cells are involved in swelling (inflammation), seizures, pain, and other conditions. By making these cells less active, cannabidivarin might improve these conditions.
There is interest in using cannabidivarin for seizure disorder, nausea, long-term swelling (inflammation) in the digestive tract, and other conditions, but there is no good scientific evidence to support these uses.
Uses
Possibly Ineffective for
- Seizure disorder (epilepsy). Taking cannabidivarin for 2 weeks doesn't appear to reduce seizures in people with poorly controlled seizure disorder.
There is interest in using cannabidivarin for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.
Side Effects
When taken by mouth: It is possibly safe to take cannabidivarin at a dose of up to 1600 mg daily, for up to 8 weeks. It might cause side effects such as diarrhea, dizziness, headache, sleepiness, and nausea. There isn't enough reliable information to know if cannabidivarin is safe when used in larger doses or for more than 8 weeks.
Precautions
When taken by mouth: It is possibly safe to take cannabidivarin at a dose of up to 1600 mg daily, for up to 8 weeks. It might cause side effects such as diarrhea, dizziness, headache, sleepiness, and nausea. There isn't enough reliable information to know if cannabidivarin is safe when used in larger doses or for more than 8 weeks.
Pregnancy and breast-feeding: There isn't enough reliable information to know if cannabidivarin is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.
Interactions
We currently have no information for Cannabidivarin (CBDV) overview.
Dosing
There isn't enough reliable information to know what an appropriate dose of cannabidivarin might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.
References
- European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for the treatment of Rett syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/17/1921-public-summary-opinion-orphan-designation-cannabidivarin-treatment-rett-syndrome_en.pdf. Accessed December 16, 2019.
- European Medicines Agency. Public summary of opinion on orphan designation: Cannabidivarin for treatment of fragile X syndrome. Available at: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/18/1977-public-summary-opinion-orphan-designation-cannabidivarin-treatment-fragile-x-syndrome_en.pdf. Accessed December 16, 2019.
- Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), ??-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl). 2012;219(3):859-73.
- Hill AJ, Mercier MS, Hill TD, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012;167(8):1629-42.
- Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679-92.
- Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology. 2019;148:189-198.
- Iannotti FA, Pagano E, Moriello AS, et al. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol. 2019;176(10):1568-1584.
- Pagano E, Romano B, Iannotti FA, et al. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacol Res. 2019;149:104464.
- Rock EM, Sticht MA, Duncan M, Stott C, Parker LA. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and ?(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol. 2013;170(3):671-8.
- Vigli D, Cosentino L, Raggi C, Laviola G, Woolley-Roberts M, De Filippis B. Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology. 2018;140:121-129.
- Zamberletti E, Gabaglio M, Piscitelli F, et al. Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice. J Psychopharmacol. 2019;33(7):894-907.
- Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D. Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. Front Cell Neurosci. 2019;13:367.
- Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131-41.
- Avau B, Borra V, Vanhove AC, Vandekerckhove P, De Paepe P, De Buck E. First aid interventions by laypeople for acute oral poisoning. Cochrane Database Syst Rev. 2018;12(12):CD013230.
- Eibach L, Scheffel S, Cardebring M, et al. Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial. Clin Pharmacol Ther. 2020.
- Pretzsch CM, Voinescu B, Lythgoe D, et al. Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy. Transl Psychiatry. 2019;9(1):313.
- US Food and Drug Administration. Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed on March 19, 2021.
- Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10(1):20405.
- Straiker A, Wilson S, Corey W, et al. An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. Molecules 2021;26(17):5352.
- Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res 2021;6(6):528-536.
- Hurley EN, Ellaway CJ, Johnson AM, et al. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia 2022;63(7):1736-1747.
- Schwarz AM, Kobeci D, Mancuso JA, et al. Select Minor Cannabinoids from Cannabis sativa Are Cannabimimetic and Antinociceptive in a Mouse Model of Chronic Neuropathic Pain. J Pharmacol Exp Ther 2024;391(2):214-221.